Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

The cholinergic hypothesis of Alzheimer's disease: a review of progress.

Francis PT, Palmer AM, Snape M, Wilcock GK.

J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47. Review.

2.
3.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID:
16437532
4.

[Pharmacology of Alzheimer's disease: where do we go from here?].

Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H, Delini-Stula A, Bentué-Ferrer D, Bordet R, Allain H.

Therapie. 2005 Mar-Apr;60(2):89-107. Review. French.

PMID:
15969312
5.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;4:CD001191.

PMID:
19370562
6.

Rivastigmine for Alzheimer's disease.

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. Review.

PMID:
25858345
7.

Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun.

8.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
9.

Acetylcholinesterase inhibition in Alzheimer's Disease.

Ibach B, Haen E.

Curr Pharm Des. 2004;10(3):231-51. Review.

PMID:
14754384
10.

The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs.

Buccafusco JJ.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 17.

11.
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
13.

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Nordberg A, Svensson AL.

Drug Saf. 1998 Dec;19(6):465-80. Review. Erratum in: Drug Saf 1999 Feb;20(2):146.

PMID:
9880090
14.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
15.

WITHDRAWN: Tacrine for Alzheimer's disease.

Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000202. Review.

PMID:
17636619
16.

Tacrine for Alzheimer's disease.

Qizilbash N, Birks J, López-Arrieta J, Lewington S, Szeto S.

Cochrane Database Syst Rev. 2000;(2):CD000202. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD000202.

PMID:
10796507
17.

Evidence-based pharmacotherapy of Alzheimer's disease.

Evans JG, Wilcock G, Birks J.

Int J Neuropsychopharmacol. 2004 Sep;7(3):351-69. Epub 2004 Jul 1. Review.

PMID:
15228642
18.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
19.

Rivastigmine for Alzheimer's disease.

Birks JS, Chong LY, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Sep 22;9:CD001191. [Epub ahead of print] Review.

PMID:
26393402
20.

Supplemental Content

Support Center